Frequency of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Patients Using Methotrexate Intolerance Severity Score
DOI:
https://doi.org/10.21649/akemu.v31i4.5831Keywords:
Juvenile idiopathic arthritis, Methotrexate, Methotrexate intolerance severity score, MISSAbstract
Background: The Methotrexate Intolerance Severity Score (MISS) is a comprehensive scoring system used to assess methotrexate intolerance.
Objective: The study aims to determine the frequency of methotrexate intolerance in JIA patients using MISS and its association with demographic factors, subtypes of JIA, duration of illness, and MTX intake.
Methods: This cross-sectional study was conducted at the Department of Rheumatology, UCHS and The Children’s Hospital, Lahore. All patients having JIA and taking MTX for at least 3 months were enrolled. Demographic data, including age, gender, subtype of JIA, duration of the disease, and MTX dosage and duration, were collected. The MISS score has four elements: abdominal pain, nausea, vomiting, and behavioral symptoms. A cutoff value of 6 or above was considered indicative of MTX intolerance. Data was analyzed into SPSS version 22.
Results: Out of 96 JIA patients, 60.4% were female and the mean age was 9.92 ± 4.11 years. Polyarticular seronegative JIA was present in 56.3% of patients. Among all patients, 22.9% had MTX intolerance according to the MISS score. Nausea was found in 58.3%, followed by behavioral symptoms in 44.8%. All MTX-intolerant patients experienced nausea and behavioral symptoms, with vomiting occurring in 59.1% and abdominal pain in 45.4%. MTX intolerance was significantly linked with increasing age in JIA patients but was not related to gender, subtype of JIA, duration of disease, and MTX intake, or MTX dose.
Conclusion: About one-third of all JIA patients were methotrexate intolerant having nausea and behavioral symptoms. MTX intolerance was significantly linked with increasing age in JIA patients taking MTX.
References
1. Wu CBF, St. Geme JW III, Blum NJ, Tasker RC. Nelson textbook of pediatrics. 21st ed. Philadelphia, PA: Elsevier Saunders; 2019:1258-68.
2. Naz S, Asif M, Naz F, Farooq H, Hamid MH. Spectrum of joint deformities in children with juvenile idiopathic arthritis. J Coll Physicians Surg Pak. 2018;28(6):470-3. DOI:10.29271/jcpsp.2018.06.470.
3. Holzinger D, Frosch M, Föll D. Methotrexat bei der Therapie der juvenilen idiopathischen Arthritis. Z Rheumatol. 2010;69(6):496-504. DOI:10.1007/s00393-010-0633-1
4. Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012;64(9):1349-56. DOI:10.1002/acr.21785.
5. Bulatovic M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W, Hoppenreijs EP, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 2011;63(7):2007-13. DOI:10.1002/art.30367
6. Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014;41(6):1049-60. DOI:10.3899/jrheum.131040.
7. Calasan MB, van den Bosch OF, Creemers MC, Custers M, Heurkens AH, van Woerkom JM, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther. 2013;15(6):217. DOI:10.1186/ar4413.
8. Asghar MA, Hashmat M, Wagan AA, Zafar ZA, Pirzada AR. Assessment of methotrexate intolerance through methotrexate intolerance severity score (MISS questionnaire) in patients with rheumatoid arthritis. Professional Med J. 2023;30(6):736-40. DOI:10.29309/TPMJ/2023.30.06.1743.
9. Salim B, Ahsin S, Bhatti AR. Frequency of methotrexate intolerance in juvenile idiopathic arthritis (JIA): An experience using Methotrexate Intolerance Severity Score (MISS). Pak Armed Forces Med J. 2013;63(1):34-7.
10. Mulligan K, Kassoumeri L, Etheridge A, Moncrieffe H, Wedderburn LR, Newman S. Mothers' reports of the difficulties that their children experience in taking methotrexate for juvenile idiopathic arthritis and how this impact quality of life. Pediatr Rheumatol Online J. 2013;11(1):23. DOI:10.1186/1546-0096-11-23.
11. Höfel L, Eppler B, Storf M, Schnöbel-Müller E, Haas JP, Hügle B. Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing—treatment protocol and preliminary results. Pediatr Rheumatol Online J. 2018;16 (1):1-6. DOI:10.1186/s12969-018-0228-y.
12. Falvey S, Shipman L, Ilowite N, Beukelman T. Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2017;15(1):52. DOI: 10.1186/s12969-017-0180-2.
13. Quesada-Masachs and Modesto: PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2013;11(2):61.DOI:10.1186/1546-0096-11-S2-P61
14. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465-82. DOI: 10.1002/acr.20460.
15. Naz S, Mushtaq A, Rehman S, Bari A, Maqsud A, Khan MZ, Ahmad TM. Juvenile rheumatoid arthritis. J Coll Physicians Surg Pak. 2013;23(6):409-12. DOI:10.2014/jcpsp.409412.
16. Tekin ZE, Kaplan MM, Polat MC, Çelikel E, Güngörer V, Kurt T, et al. Prevalence of methotrexate intolerance in juvenile idiopathic arthritis and possible risk factors: a tertiary center experience. J Pediatr Acad. 2022;3(2):60-4. DOI:10.51271/jpea-2022-184.
17. Fatimah N, Salim B, Nasim A, Hussain K, Gul H, Niazi S. Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire). Clin Rheumatol. 2016;35(5):1341-5. DOI:10.1007/s10067-016-3243-8.
18. Amaral JM, Brito MJ, Kakehasi AM. High frequency of methotrexate intolerance in longstanding rheumatoid arthritis: using the methotrexate intolerance severity score (MISS). Adv Rheumatol. 2020;60(8):43. DOI:10.1186/s42358-020-00145-5.
19. Senbel E, Tropé S, Herman-Demars H, Zinovieva E, Courbeyrette A, Clerson P, et al. Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting. Patient Prefer Adherence. 2021;15(1):751-60. DOI:10.2147/PPA.S301010.
20. Bakry R, Klein MA, Horneff G. Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis. Eur J Rheumatol. 2022;9(4):197-205. DOI:10.5152/eurjrheum.2022.21090.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Annals of King Edward Medical University
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments publications@kemu.edu.pk